Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Cash & Equivalents (2017 - 2025)

Crinetics Pharmaceuticals (CRNX) has 9 years of Cash & Equivalents data on record, last reported at $101.5 million in Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 61.62% year-over-year to $101.5 million; the TTM value through Dec 2025 reached $101.5 million, down 61.62%, while the annual FY2025 figure was $101.5 million, 61.62% down from the prior year.
  • Cash & Equivalents reached $101.5 million in Q4 2025 per CRNX's latest filing, down from $1.2 billion in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $1.2 billion in Q2 2025 and bottomed at $30.9 million in Q3 2022.
  • Average Cash & Equivalents over 5 years is $203.9 million, with a median of $142.8 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: plummeted 83.11% in 2022, then soared 861.14% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $201.2 million in 2021, then tumbled by 83.11% to $34.0 million in 2022, then surged by 61.59% to $54.9 million in 2023, then soared by 381.89% to $264.5 million in 2024, then tumbled by 61.62% to $101.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $101.5 million in Q4 2025, $1.2 billion in Q2 2025, and $94.6 million in Q1 2025.